StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Other Cardiovascular sub-franchise by Year

Other Cardiovascular sub-franchise — Worldwide reported growth YoY (%) (%)

Johnson & Johnson Other Cardiovascular sub-franchise: 4.3% in FY2025, down 2.6 pts from a year earlier.

Latest, FY2025
4.3%
Period ended Dec 28, 2025
Change on a year earlier
-2.6 pts
6.9% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below

Where the FY2025 figure comes from

“|| WW | 397 | 380 | 4.3 | 3.8 | 0.5”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Cardiovascular sub-franchise — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 20254.3%-2.6 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
FY2024Dec 29, 20246.9%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗

Cite this data

StockData. (2026). Johnson & Johnson Other Cardiovascular sub-franchise (%), annual FY2024–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt-other-cv-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.